PURPOSE: Our aim was to explore the interplay between human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections in the expression of cognitive disorders. METHODS: We performed a multi-centre cross-sectional study, enrolling three groups of asymptomatic outpatients matched for age and education: (1) HIV mono-infected; (2) HCV mono-infected; (3) HIV-HCV co-infected. All subjects were subjected to the Zung depression scale and a comprehensive neuropsychological battery. RESULTS: A total of 50 patients for each group were enrolled. Patients in the three groups did not significantly differ in the main common demographic and clinical characteristics, except for a lower proportion of past injecting drug use (IDU) in group 1 (4 %) in comparison to groups 2 (38 %, p < 0.001) and 3 (78 %, p < 0.001), a longer duration of HIV infection in group 3 in comparison to group 1 (p < 0.001) and a longer duration of HCV infection in group 3 in comparison to group 2 (p = 0.028). Overall, 39.3 % of patients showed minor cognitive impairment, with a higher proportion in group 3 (54 %) when compared to groups 1 (28 %, p = 0.015) or 2 (36 %, p = 0.108). Patients in group 3 [odds ratio (OR) 3.35, p = 0.038 when compared to group 1] and those with higher depression scores (OR 1.05, p = 0.017) showed an increased risk of cognitive impairment after adjusting for education and past injection drug use. In particular, group 3 showed worse performance in psychomotor speed tasks when compared to group 1 (p = 0.033). CONCLUSIONS: A worse cognitive performance in HIV-HCV co-infected patients was observed, suggesting an additive role of the two viruses in the pathogenesis of cognitive disorders.
PURPOSE: Our aim was to explore the interplay between human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections in the expression of cognitive disorders. METHODS: We performed a multi-centre cross-sectional study, enrolling three groups of asymptomatic outpatients matched for age and education: (1) HIV mono-infected; (2) HCV mono-infected; (3) HIV-HCV co-infected. All subjects were subjected to the Zung depression scale and a comprehensive neuropsychological battery. RESULTS: A total of 50 patients for each group were enrolled. Patients in the three groups did not significantly differ in the main common demographic and clinical characteristics, except for a lower proportion of past injecting drug use (IDU) in group 1 (4 %) in comparison to groups 2 (38 %, p < 0.001) and 3 (78 %, p < 0.001), a longer duration of HIV infection in group 3 in comparison to group 1 (p < 0.001) and a longer duration of HCV infection in group 3 in comparison to group 2 (p = 0.028). Overall, 39.3 % of patients showed minor cognitive impairment, with a higher proportion in group 3 (54 %) when compared to groups 1 (28 %, p = 0.015) or 2 (36 %, p = 0.108). Patients in group 3 [odds ratio (OR) 3.35, p = 0.038 when compared to group 1] and those with higher depression scores (OR 1.05, p = 0.017) showed an increased risk of cognitive impairment after adjusting for education and past injection drug use. In particular, group 3 showed worse performance in psychomotor speed tasks when compared to group 1 (p = 0.033). CONCLUSIONS: A worse cognitive performance in HIV-HCV co-infectedpatients was observed, suggesting an additive role of the two viruses in the pathogenesis of cognitive disorders.
Authors: Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson Journal: Hepatology Date: 2002-02 Impact factor: 17.425
Authors: Daniel M Forton; Joanna M Allsop; I Jane Cox; Gavin Hamilton; Keith Wesnes; Howard C Thomas; Simon D Taylor-Robinson Journal: AIDS Date: 2005-10 Impact factor: 4.177
Authors: Pornpun Vivithanaporn; Krista Nelles; Leah DeBlock; Stephen C Newman; M John Gill; Christopher Power Journal: J Neurol Sci Date: 2011-09-17 Impact factor: 3.181
Authors: Linas A Bieliauskas; Carla Back-Madruga; Karen L Lindsay; Elizabeth C Wright; Ziad Kronfol; Anna S F Lok; Robert J Fontana Journal: J Int Neuropsychol Soc Date: 2007-05-18 Impact factor: 2.892
Authors: Sérgio Monteiro de Almeida; Ana Paula de Pereira; Maria Lucia Alves Pedroso; Clea E Ribeiro; Indianara Rotta; Bin Tang; Anya Umlauf; Donald Franklin; Rowan G Saloner; Maria Geny Ribas Batista; Scott Letendre; Robert K Heaton; Ronald J Ellis; Mariana Cherner Journal: J Neurovirol Date: 2018-03-07 Impact factor: 2.643
Authors: A Calcagno; S Nozza; C Muss; B M Celesia; F Carli; S Piconi; G V De Socio; A M Cattelan; G Orofino; D Ripamonti; A Riva; G Di Perri Journal: Infection Date: 2015-05-19 Impact factor: 3.553
Authors: Robert H Paul; Cecilia M Shikuma; Nguyen Van Vinh Chau; Lishomwa C Ndhlovu; Nguyen Tat Thanh; Andrew C Belden; Dominic C Chow; Glen M Chew; Thomas A Premeaux; Vo Trieu Ly; Joseph A D McBride; Jacob D Bolzenius; Thuy Le Journal: Front Neurol Date: 2021-03-12 Impact factor: 4.003
Authors: Sam Nightingale; Alan Winston; Scott Letendre; Benedict D Michael; Justin C McArthur; Saye Khoo; Tom Solomon Journal: Lancet Neurol Date: 2014-11 Impact factor: 44.182